ET 18-OCH₃

Biological Activity

ET 18-OCH₃ is a synthetic lysophospholipid analog that selectively inhibits phosphatidylinositol phospholipase C (IC₅₀ = 9.6 μM in fibroblasts and adenocarcinoma cells). ET 18-OCH₃ acts as an agonist at platelet-activating factor (PAF) receptors. ET 18-OCH₃ is an antitumor lipid that selectively induces apoptosis in tumor cells, sparing normal cells, and activates the intracellular Fas/CD95 death receptor. ETH 18-OCH₃ also triggers eryptosis and interacts with mitochondrial membranes to increase mitochondrial membrane permeability, leading to dysfunction and apoptosis. Racemic mixture.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
   Powis et al.
   Cancer Res., 1992;52:2835
2. A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor.
   Aoki et al.
   J.Immunol.Methods, 1995;186:225
3. Roles of brain phosphatidylinositol-specific phospholipase C and diacylglycerol lipase in centrally administered histamine-induced adrenomedullary outflow in rats.
   Shimizu et al.
   Eur.J.Pharmacol., 2007;571:138
4. Phospholipase C and myosin light chain kinase inhibition define a common step in actin regulation during cytokinesis.
   Wong et al.
   BMC Cell Biol., 2007;8:15

Product Datasheets